# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+...
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) ...
Stifel analyst Stephen Willey maintains Cue Biopharma (NASDAQ:CUE) with a Buy and maintains $8 price target.
Oppenheimer analyst Leland Gershell maintains Cue Biopharma (NASDAQ:CUE) with a Outperform and maintains $10 price target.
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.27...
Piper Sandler analyst Edward Tenthoff reiterates Cue Biopharma (NASDAQ:CUE) with a Overweight and maintains $8 price target.
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported b...